HomeCompareCTBO vs MO

CTBO vs MO: Dividend Comparison 2026

CTBO yields 198.02% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTBO wins by $112.62M in total portfolio value
10 years
CTBO
CTBO
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full CTBO calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — CTBO vs MO

📍 CTBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTBOMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTBO + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTBO pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTBO
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, CTBO beats the other by $48,029,701.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTBO + MO for your $10,000?

CTBO: 50%MO: 50%
100% MO50/50100% CTBO
Portfolio after 10yr
$56.39M
Annual income
$28,281,734.09/yr
Blended yield
50.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

CTBO
No analyst data
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTBO buys
0
MO buys
11
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$MO▲ Buy$1,000 - $15,0002025-08-04
Sheri Biggs🏢 House$MO▼ Sell$1,001 - $15,0002025-03-19
Pete Sessions🏢 House$MO▼ Sell$1,001 - $15,0002024-09-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-03-20
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-02-13
Virginia Foxx🏢 House$MO▼ Sell$1,001 - $15,0002024-01-16
Virginia Foxx🏢 House$MO▲ Buy$1,001 - $15,0002024-01-11
Ro Khanna🏢 House$MO▼ Sell$1,001 - $15,0002024-01-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-01-10
Virginia Foxx🏢 House$MO▼ Sell$15,001 - $50,0002024-01-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTBOMO
Forward yield198.02%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$112.70M$77.7K
Annual income after 10y$56,534,499.65$28,968.54
Total dividends collected$106.15M$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CTBO vs MO ($10,000, DRIP)

YearCTBO PortfolioCTBO Income/yrMO PortfolioMO Income/yrGap
1← crossover$30,502$19,801.98$10,558$768.31+$19.9KCTBO
2$89,086$56,448.56$11,352$1,015.87+$77.7KCTBO
3$249,403$154,080.96$12,482$1,367.86+$236.9KCTBO
4$670,003$403,142.26$14,103$1,883.39+$655.9KCTBO
5$1,729,066$1,012,162.66$16,472$2,664.91+$1.71MCTBO
6$4,291,289$2,441,188.37$20,024$3,897.79+$4.27MCTBO
7$10,253,990$5,662,310.92$25,537$5,933.74+$10.23MCTBO
8$23,616,660$12,644,890.45$34,478$9,476.77+$23.58MCTBO
9$52,487,868$27,218,041.68$49,776$16,022.63+$52.44MCTBO
10$112,696,518$56,534,499.65$77,699$28,968.54+$112.62MCTBO

CTBO vs MO: Complete Analysis 2026

CTBOStock

Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.

Full CTBO Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this CTBO vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTBO vs SCHDCTBO vs JEPICTBO vs OCTBO vs KOCTBO vs MAINCTBO vs PMCTBO vs BTICTBO vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.